We are live on ! Find out more
OTLK icon

Outlook Therapeutics
OTLK

82 hedge funds and large institutions have $29.7M invested in Outlook Therapeutics in 2023 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 34 increasing their positions, 8 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

325% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 8

100% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 7

9% more funds holding

Funds holding: 75 → 82 (+7)

0% more capital invested

Capital invested by funds: $29.6M → $29.7M (+$125K)

0.07% less ownership

Funds ownership: 0.61% → 0.53% (-0.07%)

Holders
82
Holders Change
+7
Holders Change %
+9.33%
% of All Funds
1.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
34
Reduced
8
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$1.14M
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$532K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$389K
4
Millennium Management
Millennium Management
New York
+$382K
5
Northern Trust
Northern Trust
Illinois
+$287K

Top Sellers

Rank Fund Capital Flow
1
ACM
Altium Capital Management
New York
-$3.59M
2
GCP
GSA Capital Partners
United Kingdom
-$201K
3
Goldman Sachs
Goldman Sachs
New York
-$130K
4
VF
Vista Finance
Missouri
-$67.1K
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$53.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
51
Alamar Capital Management
California
$21.8K – – –
Legal & General Group
52
Legal & General Group
United Kingdom
$20.7K +$7.41K +331 +53%
AB
53
Amalgamated Bank
New York
$20K +$1.03K +46 +5%
ProShare Advisors
54
ProShare Advisors
Maryland
$19.8K +$3.31K +148 +19%
Principal Financial Group
55
Principal Financial Group
Iowa
$18.5K +$3K +134 +19%
SEIA
56
Signature Estate & Investment Advisors
California
$17K +$17.6K +787 New
GSIAS
57
Garden State Investment Advisory Services
New Jersey
$15.3K – – –
Victory Capital Management
58
Victory Capital Management
Texas
$15K -$1.5K -67 -9%
Fisher Asset Management
59
Fisher Asset Management
Washington
$13.6K +$14K +624 New
MFGP
60
Marshall Financial Group (Pennsylvania)
Pennsylvania
$12.9K – – –
Cetera Investment Advisers
61
Cetera Investment Advisers
Illinois
$12.9K +$13.2K +590 New
CAPTRUST Financial Advisors
62
CAPTRUST Financial Advisors
North Carolina
$11.5K +$11.8K +528 New
SEI Investments
63
SEI Investments
Pennsylvania
$11.5K +$11.8K +527 New
EWM
64
Endurance Wealth Management
Rhode Island
$11K +$11.2K +500 New
CB
65
CNB Bank
Pennsylvania
$10.9K – – –
CCM
66
Crew Capital Management
Ohio
$10.9K – – –
FMI
67
F/M Investments
District of Columbia
$10.9K – – –
GC
68
Grimes & Company
Massachusetts
$10.9K – – –
IAMOG
69
Investors Asset Management of Georgia
Georgia
$10.9K – – –
TCA
70
Transcend Capital Advisors
New Jersey
$10.9K – – –
Royal Bank of Canada
71
Royal Bank of Canada
Ontario, Canada
$10K -$8.93K -399 -45%
UBS Group
72
UBS Group
Switzerland
$9.94K -$10.1K -453 -50%
MLICM
73
Metropolitan Life Insurance Company (MetLife)
New York
$9.36K +$9.6K +429 New
AIP
74
Ameritas Investment Partners
Nebraska
$7.49K – – –
Fidelity Investments
75
Fidelity Investments
Massachusetts
$4.94K -$6.71K -300 -57%
1 2
3
4

OTLK Hedge Fund Activity: Q1 2023 in Review

82 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q1 2023, worth a combined $29.7M — up 0.42% from $29.6M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new OTLK positions and 7 closed out — a net gain of 7 holders — while 34 added to existing stakes and 8 trimmed.

The largest buyer was BlackRock, adding an estimated $1.14M. The largest seller was Altium Capital Management, exiting entirely with an estimated $3.59M sold.

  • 82 institutional investors held Outlook Therapeutics (OTLK) as of Q1 2023, up from 75 in Q4 2022.
  • Funds reported $29.7M of Outlook Therapeutics stock for Q1 2023, up 0.42% quarter-over-quarter.
  • 14 funds opened new Outlook Therapeutics positions in Q1 2023 and 7 closed out, a net change of +7 holders.
  • The largest Outlook Therapeutics buyer in Q1 2023 was BlackRock, an estimated $1.14M added.
  • The largest Outlook Therapeutics seller in Q1 2023 was Altium Capital Management, an estimated $3.59M sold.

Based on aggregated 13F filings for Q1 2023.